XTX Topco Ltd Acquires 39,358 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

XTX Topco Ltd boosted its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 296.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,651 shares of the biotechnology company’s stock after purchasing an additional 39,358 shares during the period. XTX Topco Ltd owned about 0.11% of REGENXBIO worth $616,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Hsbc Holdings PLC raised its holdings in shares of REGENXBIO by 37.1% in the 2nd quarter. Hsbc Holdings PLC now owns 19,916 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 5,389 shares during the period. Amalgamated Bank raised its stake in shares of REGENXBIO by 9.9% in the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,227 shares during the period. WINTON GROUP Ltd lifted its position in shares of REGENXBIO by 79.9% during the 2nd quarter. WINTON GROUP Ltd now owns 76,840 shares of the biotechnology company’s stock valued at $899,000 after buying an additional 34,136 shares during the last quarter. American Century Companies Inc. grew its stake in shares of REGENXBIO by 16.8% during the 2nd quarter. American Century Companies Inc. now owns 74,872 shares of the biotechnology company’s stock worth $876,000 after acquiring an additional 10,767 shares during the period. Finally, Quest Partners LLC increased its holdings in REGENXBIO by 11,731.0% in the 2nd quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 41,645 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, Director Argeris N. Karabelas sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $169,741.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Argeris N. Karabelas sold 11,000 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $15.04, for a total value of $165,440.00. Following the transaction, the director now owns 11,286 shares of the company’s stock, valued at $169,741.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kenneth T. Mills sold 2,210 shares of REGENXBIO stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $13.77, for a total value of $30,431.70. Following the transaction, the director now directly owns 408,035 shares in the company, valued at $5,618,641.95. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,279 shares of company stock valued at $875,634. 13.13% of the stock is owned by company insiders.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $11.67 on Tuesday. The firm has a market cap of $574.82 million, a P/E ratio of -1.98 and a beta of 1.22. REGENXBIO Inc. has a fifty-two week low of $10.49 and a fifty-two week high of $28.80. The firm has a 50-day simple moving average of $12.49 and a two-hundred day simple moving average of $14.86.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million during the quarter, compared to analyst estimates of $22.97 million. During the same period in the previous year, the business earned ($1.66) EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities research analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on RGNX. Barclays dropped their price objective on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research note on Wednesday, September 4th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday. Finally, The Goldman Sachs Group assumed coverage on shares of REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.91.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.